The Challenge

• Glioblastoma (GBM) and Neurofibromatosis (NF) remain devastating diseases with few effective treatments

• There are a lack of predictive preclinical models for these diseases

• Human clinical trials are challenging due to a small number of patients

The Solution

• Precisely gene-edited Therillume™ model pigs that faithfully replicate human GBM will be used to conduct faster, robust, cost effective and predictive surrogate clinical trials of Therillume™ therapeutics for GBM and NF1&2

Therillume™

• Is the pioneer and world’s leading precise gene-editing company for large animals.

• Has made the first gene edited large animal (swine) models of GBM and NF1 and NF2

• Models are engineered with the same driver mutations found in human patients

• Models faithfully replicate human GBM pathology and molecular subtypes

• Is using the models to run surrogate clinical trials to validate and optimize therapeutics

• Gene-editing platform has been developed with over $25M in non-dilutive grants

• Underlying platform featured in over 75 publications including Nature, Nature Biotechnology, Nature Medicine, Nature Methods, PNAS, etc.